Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy

MeSH terms

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents / therapeutic use*
• Benzamides / therapeutic use*
• Drug Monitoring
• Female
• Fusion Proteins, bcr-abl / genetics*
• Gene Expression
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
• Male
• Middle Aged
• Piperazines / therapeutic use*
• Prognosis
• Prospective Studies
• Pyrimidines / therapeutic use*
• RNA, Messenger / genetics*
• Risk
• Survival Analysis
• Treatment Outcome